Aratana files for first drug approval in U.S.; shares up 8% premarket

• Companion animal drug developer Aratana Therapeutics (NASDAQ:PETX) is up 8% premarket on modest volume in response to its announcement that it has filed its first New Animal Drug Application (NADA) with the FDA seeking clearance of Galliprant (grapiprant) for the control of pain and inflammation in dogs with osteoarthritis.
• The FDA's action date (ADUFA) is March 25.